These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 26422398)

  • 1. A Case Report of Unresectable Cutaneous Squamous Cell Carcinoma Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 Inhibitor.
    Chang AL; Kim J; Luciano R; Sullivan-Chang L; Colevas AD
    JAMA Dermatol; 2016 Jan; 152(1):106-8. PubMed ID: 26422398
    [No Abstract]   [Full Text] [Related]  

  • 2. Follow-up on Programmed Cell Death 1 Inhibitor for Cutaneous Squamous Cell Carcinoma.
    Tran DC; Colevas AD; Chang AL
    JAMA Dermatol; 2017 Jan; 153(1):92-94. PubMed ID: 27784038
    [No Abstract]   [Full Text] [Related]  

  • 3. Patterns of response and acquired resistance to the programmed death-1 inhibitor pembrolizumab in Stage III metastatic cutaneous squamous cell carcinoma.
    Zalaudek I; Corneli P; Vernoni S; Fedele D; Papa G; Conforti C; Retrosi C; Vezzoni R; Fagotti S; Longone M; Farinazzo E; di Meo N; Pizzichetta MA
    Dermatol Ther; 2019 Nov; 32(6):e13107. PubMed ID: 31595596
    [No Abstract]   [Full Text] [Related]  

  • 4. Rescue therapy with anti-programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in five cases.
    Borradori L; Sutton B; Shayesteh P; Daniels GA
    Br J Dermatol; 2016 Dec; 175(6):1382-1386. PubMed ID: 27059424
    [No Abstract]   [Full Text] [Related]  

  • 5. Anti-programmed cell death-1 therapy in nonmelanoma skin cancer.
    Winkler JK; Schneiderbauer R; Bender C; Sedlaczek O; Fröhling S; Penzel R; Enk A; Hassel JC
    Br J Dermatol; 2017 Feb; 176(2):498-502. PubMed ID: 27061826
    [No Abstract]   [Full Text] [Related]  

  • 6. Expression of Programmed Cell Death Ligand in Cutaneous Squamous Cell Carcinoma and Treatment of Locally Advanced Disease With Pembrolizumab.
    Stevenson ML; Wang CQ; Abikhair M; Roudiani N; Felsen D; Krueger JG; Pavlick AC; Carucci JA
    JAMA Dermatol; 2017 Apr; 153(4):299-303. PubMed ID: 28259107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pembrolizumab for the treatment of melanoma.
    Kumar SS; McNeil CM
    Expert Rev Clin Pharmacol; 2015; 8(5):515-27. PubMed ID: 26146011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of unresectable cutaneous squamous cell carcinoma with pembrolizumab.
    Venkatesh S; Al-Haseni A; Sahni D
    BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31377718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple keratin granulomata: A potential histologic clue to cutaneous squamous cell carcinoma responding to programmed cell death protein 1 inhibitor therapy.
    Kahn BJ; Parker D; Yushak M; Stoff B; Blalock TW
    J Cutan Pathol; 2019 Jun; 46(6):452-454. PubMed ID: 30811629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1 Blockers.
    Wolchok JD
    Cell; 2015 Aug; 162(5):937. PubMed ID: 26317459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmed death protein 1 inhibitors making inroads in multiple cancers.
    Brower V
    J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25957444
    [No Abstract]   [Full Text] [Related]  

  • 12. Cutaneous Metastatic Melanoma Resembling a Halo Nevus, in the Setting of PD-1 Inhibition.
    Harvey NT; Millward M; Macgregor K; Bucat RP; Wood BA
    Am J Dermatopathol; 2016 Dec; 38(12):e159-e162. PubMed ID: 27870733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer.
    Dang TO; Ogunniyi A; Barbee MS; Drilon A
    Expert Rev Anticancer Ther; 2016; 16(1):13-20. PubMed ID: 26588948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged Response to Pembrolizumab in Spindle Cell Squamous Cell Carcinoma Metastatic to the Central Nervous System.
    Liu Y; Fitzgerald B; Perry E; Pathak A; Chao HH
    J Investig Med High Impact Case Rep; 2019; 7():2324709619850216. PubMed ID: 31132886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab (Keytruda) for first-line treatment of metastatic NSCLC.
    Med Lett Drugs Ther; 2017 Jan; 59(1513):22-23. PubMed ID: 28118650
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety of pembrolizumab for the treatment of melanoma.
    Martin-Liberal J; Kordbacheh T; Larkin J
    Expert Opin Drug Saf; 2015 Jun; 14(6):957-64. PubMed ID: 25927979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eruptive cutaneous squamous cell carcinoma and psoriasis: response to cetuximab.
    Kamaria M; Shea CR; Chin RK; Cohen EE; Maggiore R; Bolotin D
    Clin Exp Dermatol; 2014 Jul; 39(5):604-7. PubMed ID: 24758726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel treatments using PD1 inhibitors for advanced and metastatic cutaneous squamous cell carcinoma.
    Pezeshki S; Hemmati S; Rezaei N
    Expert Rev Anticancer Ther; 2020 Oct; 20(10):819-822. PubMed ID: 32852235
    [No Abstract]   [Full Text] [Related]  

  • 19. Rapid response of metastatic cutaneous squamous cell carcinoma to pembrolizumab in a patient with xeroderma pigmentosum: Case report and review of the literature.
    Deinlein T; Lax SF; Schwarz T; Giuffrida R; Schmid-Zalaudek K; Zalaudek I
    Eur J Cancer; 2017 Sep; 83():99-102. PubMed ID: 28734147
    [No Abstract]   [Full Text] [Related]  

  • 20. Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma.
    Lavaud J; Blom A; Longvert C; Fort M; Funck-Brentano E; Saiag P
    Eur J Dermatol; 2019 Dec; 29(6):636-640. PubMed ID: 31903954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.